Cargando…

Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study

PURPOSE: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS(™) study. PATIENTS AND METHODS: LUMINOUS, a 5-year, prospective, multicenter, observati...

Descripción completa

Detalles Bibliográficos
Autores principales: Holz, Frank G., Minnella, Angelo M., Tuli, Raman, Yoganathan, Pradeepa, Parikh, Soumil, Hamilton, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773197/
https://www.ncbi.nlm.nih.gov/pubmed/33378369
http://dx.doi.org/10.1371/journal.pone.0244183
_version_ 1783630013236510720
author Holz, Frank G.
Minnella, Angelo M.
Tuli, Raman
Yoganathan, Pradeepa
Parikh, Soumil
Hamilton, Robin
author_facet Holz, Frank G.
Minnella, Angelo M.
Tuli, Raman
Yoganathan, Pradeepa
Parikh, Soumil
Hamilton, Robin
author_sort Holz, Frank G.
collection PubMed
description PURPOSE: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS(™) study. PATIENTS AND METHODS: LUMINOUS, a 5-year, prospective, multicenter, observational study, recruited 30,138 adult patients (treatment-naïve or prior ranibizumab-treated or other ocular treatments) across all approved indications for ranibizumab. Patients were treated as per local ranibizumab label of participating countries. Here we report the mean change in visual acuity (VA) at Year 1, treatment exposure, overall incidence of ocular, non-ocular adverse events (AEs) and serious AEs (SAEs) in prior ranibizumab-treated nAMD patients (n = 16,167). RESULTS: At baseline, the mean (standard deviation [SD]) age of patients was 78.4 (9.0) years, 59.0% were female, and 80.0% were Caucasian. At Year 1 (n = 10,168), the mean (SD) VA change was −1.6 (12.6) letters (baseline VA: 58.3 [19.0] letters) with a mean (SD) of 4.7 (3.1) ranibizumab injections. Stratified by duration of prior ranibizumab treatment of <1 (n = 4,112), 1 to <2 (n = 2,095), 2 to <3 (n = 1,506), 3 to <4 (n = 1,123), 4 to <5 (n = 689), and ≥5 (n = 256) years, the mean (SD) VA change at Year 1 were −1.2 (13.5), −2.0 (12.3), −2.0 (11.3), −1.9 (11.8), −2.5 (10.9), and 0.0 (11.2) letters, respectively. Mean (SD) VA change in patients who received ≤6 and >6 injections over 1 year was −1.8 (13.8) and +0.5 (12.5) letters, respectively. The rate of ocular/non-ocular AEs and SAEs across all prior ranibizumab-treated patients over 5 years were 13.29%/23.02% and 0.84%/13.66%, respectively. CONCLUSIONS: Overall, regardless of the prior ranibizumab-treatment duration, VA was maintained in these patients at Year 1, and those receiving ≥6 injections showed a trend towards gaining letters. There were no new safety signals. These results may help inform routine clinical practice to appropriately treat nAMD patients with ranibizumab to achieve optimal visual outcomes.
format Online
Article
Text
id pubmed-7773197
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77731972021-01-08 Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study Holz, Frank G. Minnella, Angelo M. Tuli, Raman Yoganathan, Pradeepa Parikh, Soumil Hamilton, Robin PLoS One Research Article PURPOSE: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in prior ranibizumab-treated patients with neovascular age-related macular degeneration (nAMD) enrolled in the LUMINOUS(™) study. PATIENTS AND METHODS: LUMINOUS, a 5-year, prospective, multicenter, observational study, recruited 30,138 adult patients (treatment-naïve or prior ranibizumab-treated or other ocular treatments) across all approved indications for ranibizumab. Patients were treated as per local ranibizumab label of participating countries. Here we report the mean change in visual acuity (VA) at Year 1, treatment exposure, overall incidence of ocular, non-ocular adverse events (AEs) and serious AEs (SAEs) in prior ranibizumab-treated nAMD patients (n = 16,167). RESULTS: At baseline, the mean (standard deviation [SD]) age of patients was 78.4 (9.0) years, 59.0% were female, and 80.0% were Caucasian. At Year 1 (n = 10,168), the mean (SD) VA change was −1.6 (12.6) letters (baseline VA: 58.3 [19.0] letters) with a mean (SD) of 4.7 (3.1) ranibizumab injections. Stratified by duration of prior ranibizumab treatment of <1 (n = 4,112), 1 to <2 (n = 2,095), 2 to <3 (n = 1,506), 3 to <4 (n = 1,123), 4 to <5 (n = 689), and ≥5 (n = 256) years, the mean (SD) VA change at Year 1 were −1.2 (13.5), −2.0 (12.3), −2.0 (11.3), −1.9 (11.8), −2.5 (10.9), and 0.0 (11.2) letters, respectively. Mean (SD) VA change in patients who received ≤6 and >6 injections over 1 year was −1.8 (13.8) and +0.5 (12.5) letters, respectively. The rate of ocular/non-ocular AEs and SAEs across all prior ranibizumab-treated patients over 5 years were 13.29%/23.02% and 0.84%/13.66%, respectively. CONCLUSIONS: Overall, regardless of the prior ranibizumab-treatment duration, VA was maintained in these patients at Year 1, and those receiving ≥6 injections showed a trend towards gaining letters. There were no new safety signals. These results may help inform routine clinical practice to appropriately treat nAMD patients with ranibizumab to achieve optimal visual outcomes. Public Library of Science 2020-12-30 /pmc/articles/PMC7773197/ /pubmed/33378369 http://dx.doi.org/10.1371/journal.pone.0244183 Text en © 2020 Holz et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Holz, Frank G.
Minnella, Angelo M.
Tuli, Raman
Yoganathan, Pradeepa
Parikh, Soumil
Hamilton, Robin
Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
title Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
title_full Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
title_fullStr Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
title_full_unstemmed Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
title_short Ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: Real-world outcomes from the LUMINOUS study
title_sort ranibizumab treatment patterns in prior ranibizumab-treated neovascular age-related macular degeneration patients: real-world outcomes from the luminous study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773197/
https://www.ncbi.nlm.nih.gov/pubmed/33378369
http://dx.doi.org/10.1371/journal.pone.0244183
work_keys_str_mv AT holzfrankg ranibizumabtreatmentpatternsinpriorranibizumabtreatedneovascularagerelatedmaculardegenerationpatientsrealworldoutcomesfromtheluminousstudy
AT minnellaangelom ranibizumabtreatmentpatternsinpriorranibizumabtreatedneovascularagerelatedmaculardegenerationpatientsrealworldoutcomesfromtheluminousstudy
AT tuliraman ranibizumabtreatmentpatternsinpriorranibizumabtreatedneovascularagerelatedmaculardegenerationpatientsrealworldoutcomesfromtheluminousstudy
AT yoganathanpradeepa ranibizumabtreatmentpatternsinpriorranibizumabtreatedneovascularagerelatedmaculardegenerationpatientsrealworldoutcomesfromtheluminousstudy
AT parikhsoumil ranibizumabtreatmentpatternsinpriorranibizumabtreatedneovascularagerelatedmaculardegenerationpatientsrealworldoutcomesfromtheluminousstudy
AT hamiltonrobin ranibizumabtreatmentpatternsinpriorranibizumabtreatedneovascularagerelatedmaculardegenerationpatientsrealworldoutcomesfromtheluminousstudy
AT ranibizumabtreatmentpatternsinpriorranibizumabtreatedneovascularagerelatedmaculardegenerationpatientsrealworldoutcomesfromtheluminousstudy